Alfred Health leads AI trial for epilepsy treatment | Healthcare Asia Magazine
, Australia
Photo from The Alfred Health website

Alfred Health leads AI trial for epilepsy treatment

Two groups are monitored for 12 months, with findings used to refine the AI model.

Australia’s Alfred Health is the lead site for PERSONAL, a clinical trial evaluating the use of artificial intelligence (AI) in prescribing epilepsy medication.

The trial will monitor two groups for 12 months, with findings used to refine the AI model and enhance its accuracy in epilepsy treatment.

One group’s doctor receives support from the model when prescribing medication, whilst the other prescribes without AI assistance. Participants are unaware of their group allocation.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

Alfred Health leads AI trial for epilepsy treatment
Two groups are monitored for 12 months, with findings used to refine the AI model.
Healthcare
Aster Medcity unveils upgraded endocrinology department
It offers diagnosis, treatment, and management for different endocrine disorders.
Healthcare
Biopsy devices market to be valued at $11.01b by 2030
However, underdeveloped healthcare infrastructures will limit growth.
Healthcare

Exclusives

Singapore told to harness medical tourism
It is missing out on the region’s lucrative market, which could grow to $172.1b by 2032.
Healthcare
Thomson Medical to open second fertility hub
The Singapore-based hospital operator has upgraded its hardware to meet patient needs.